Loading
Ainos, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by chiang yao-chung, was filed 09 Jun 2026.
Ainos, Inc.: what insiders have been doing
Ainos, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). From 20 October 2025 to 20 October 2026, the disclosure feed for Ainos, Inc. logged 25 filings by 9 insiders.
Both sides are active: 6 purchases worth €14k and 8 sales worth €418k, from 1 insider and 3 insiders respectively. The net balance comes to €404k on the selling side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The buyers include 1 senior executive. Lee Ting-Chuan filed the largest sale, €180k, on 27 May 2026.
The last purchase on record was published on 9 June 2026, which is 133 days ago. Typically, a trade is published a median of 1 day after it takes place. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Compared with its exchange (5,454 companies, median 22 filings), a count of 25 filings is above the norm. Since 2021, the database holds 13 purchases and 18 sales by insiders of the company. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 124,157 USD and net income at -14.8 m USD.
Other companies in the same sector with recent insider buying flagged by our signals: Vivos Inc and Anixa Biosciences Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
109
Thresholds
n/a
Buy Volume
€1M
13 ops. · all time
Sell Volume
€769,215
18 ops. · all time
Who traded when
BuySaleTaiwan Carbon Nano Technology Corp9 sales
Yao-Chung Chiang6 buys
Chun-Jung Tsai4 sales
Ting-Chuan Lee4 sales
ASE Test, Inc.1 buy
Since the insiders bought
- -56.9%Entry US$1.89 · Close 19 Oct 2026 US$0.81
- -74.0%Entry US$20.02 · Close at T+365 US$5.20
- -40.2%Entry US$27.13 · Close at T+365 US$16.23
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.81
Analyst consensus
Income statement
RevenueUS$124.2k
Gross profitUS$102.9k83% margin
EBITDA-US$9.3M-7473% margin
Net income-US$14.8M-11897.0% margin
Valuation
P/Book1.8x
Beta2.48
Balance sheet & cash
Market capUS$6M
Total debtUS$11M
Free Cash Flow-US$4.6M
Debt / Equity421%
Profitability & ownership
ROE-196.3%
ROA-39.6%
% insiders70.9%
% institutions2.3%
Last declaration on 9 June 2026
Declarations109 total
3,500 shares@ US$2.051.1% of flowCommon StockSEC:0001493152-26-027881:0
Canonical exit: 3 Sept 2026 (T+90)
2,000 shares@ US$2.130.6% of flowCommon StockSEC:0001493152-26-027488:0
Canonical exit: 1 Sept 2026 (T+90)
250 shares@ US$2.300.1% of flowCommon StockSEC:0001493152-26-026617:0
Canonical exit: 26 Aug 2026 (T+90)
2,000 shares@ US$2.000.6% of flowCommon StockSEC:0001493152-26-026361:0
Canonical exit: 25 Aug 2026 (T+90)
1,082 shares@ US$1.550.1% of flowCommon StockSEC:0001493152-26-025482:0
27,718 shares@ US$1.873.6% of flowCommon StockSEC:0001493152-26-025482:1
41,000 shares@ US$2.3634.9% of flowCommon StockSEC:0001493152-26-025484:0
109,988 shares@ US$1.909.3% of flowCommon StockSEC:0001493152-26-025486:0
9,000 shares@ US$1.560.6% of flowCommon StockSEC:0001493152-26-025246:0
9,302 shares@ US$1.570.7% of flowCommon StockSEC:0001493152-26-025246:1
100 shares@ US$1.750.0% of flowCommon StockSEC:0001493152-26-020893:0
Canonical exit: 28 Jul 2026 (T+90)
200 shares@ US$1.680.0% of flowCommon StockSEC:0001493152-26-020893:1
Canonical exit: 29 Jul 2026 (T+90)
330,000 shares@ US$1.6136.6% of flowCommon StockSEC:0001493152-26-017859:0
570,000 shares@ US$1.6140.3% of flowCommon StockSEC:0001493152-26-017844:0
300,000 shares@ US$1.6116.7% of flowCommon StockSEC:0001493152-26-017846:0
46,000 shares@ US$2.169734.8% of flowCommon StockSEC:0001493152-26-004287:0
850 shares@ US$1.80480.6% of flowCommon StockSEC:0001493152-26-001852:0
50,000 shares@ US$2.1030.3% of flowCommon StockSEC:0001493152-25-025151:0
80,000 shares@ US$2.1011.9% of flowCommon StockSEC:0001493152-25-025150:0
50,000 shares@ US$2.1015.7% of flowCommon StockSEC:0001493152-25-025149:0
80,000 shares@ US$2.106.0% of flowCommon StockSEC:0001493152-25-025148:0
50,000 shares@ US$2.107.7% of flowCommon StockSEC:0001493152-25-025147:0
20,000 shares@ US$2.1023.9% of flowCommon StockSEC:0001493152-25-025146:0
50,000 shares@ US$2.1030.3% of flowCommon StockSEC:0001493152-25-025145:0
80,000 shares@ US$2.107.6% of flowCommon StockSEC:0001493152-25-025144:0
25 of 109 declarations
About Ainos, Inc.
Ainos, Inc. is a U.S.-based healthcare and medtech company listed on NASDAQ in the United States under the symbols AIMD and AIMDW. For French, Belgian, and Swiss investors, it is best viewed as a small-cap R&D-driven name at the intersection of biotechnology, diagnostics, and applied artificial intelligence. The company traces its roots back to 1984, when it was founded around low-dose interferon alpha research. Over time, Ainos expanded and has more recently repositioned itself as a diversified medtech platform centered on three business pillars: low-dose interferon therapeutics, point-of-care diagnostic devices, and its proprietary AI Nose platform, which is designed to convert odor signals into machine-readable data for AI applications. ([ainos.com](https://www.ainos.com/?utm_source=openai))
Ainos’ U.S. operating headquarters is now in Houston, Texas, following an announced relocation from San Diego. The company also maintains a Taiwan presence, reflecting a bi-regional operating model that combines clinical development, intellectual property generation, and industrial partnerships. Ainos says it holds more than 60 patents in total, including over 50 digital nose-related patents, which is central to its differentiation in a niche and still early-stage technology category. ([ainos.com](https://ainos.com/news_view/89?utm_source=openai))
Read moreShow less
From a product standpoint, Ainos is developing and/or commercializing several product families: VELDONA, its low-dose oral interferon program; AI Nose, its scent-intelligence platform; and diagnostic applications such as Ainos Flora, Ainos Pen, antigen test kits, and other point-of-care tools. The company’s competitive position is that of a specialized innovator rather than a scaled commercial healthcare platform. Its strategy is aimed at markets with potentially large addressable opportunities but relatively low current penetration, including hygiene monitoring, industrial environments, connected healthcare, and selected clinical-use cases. ([ainos.com](https://www.ainos.com/?utm_source=openai))
Recent corporate developments have been centered on the commercialization push for AI Nose. In 2025, Ainos launched its first commercial AI Nose module and announced pilot and partnership activity in Japan and with ASE Technology Holding, including a reported ambition to deploy up to 15,000 units across selected sites. In May 2026, the company said execution on AI Nose was advancing in semiconductor and healthcare infrastructure settings, indicating movement from validation toward broader deployment readiness. For investors, Ainos remains a highly speculative transformation story, dependent on execution, future financing, and the ability to convert intellectual property into recurring revenue streams. ([ainos.com](https://ainos.com/news_view/78?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
